APA

Marre M., Shaw J., Brändle M., Bebakar W. M. W., Kamaruddin N. A., Strand J., Zdravkovic M., Le Thi T. D. & Colagiuri S. (20090910). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). : Diabetic medicine : a journal of the British Diabetic Association.

Chicago

Marre M, Shaw J, Brändle M, Bebakar W M W, Kamaruddin N A, Strand J, Zdravkovic M, Le Thi T D and Colagiuri S. 20090910. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). : Diabetic medicine : a journal of the British Diabetic Association.

Harvard

Marre M., Shaw J., Brändle M., Bebakar W. M. W., Kamaruddin N. A., Strand J., Zdravkovic M., Le Thi T. D. and Colagiuri S. (20090910). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). : Diabetic medicine : a journal of the British Diabetic Association.

MLA

Marre M, Shaw J, Brändle M, Bebakar W M W, Kamaruddin N A, Strand J, Zdravkovic M, Le Thi T D and Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). : Diabetic medicine : a journal of the British Diabetic Association. 20090910.